@article{ref1,
title="Sulbactam/ampicillin in the treatment of skin and soft-tissue infections due of methicillin-resistance staphylococci. A pilot study",
journal="Current therapeutic research, clinical and experimental",
year="1991",
author="Andreoni, M. and Raillard, P. and Concia, E. and Wang, Y.",
volume="50",
number="3",
pages="386-395",
abstract="Nineteen patients presenting with bacteriologically proven skin and soft-tissue infections caused by methicillin-resistant staphylococci were treated with parenteral sulbactam/ampicillin, a combination of the beta-lactam antibiotic ampicillin and the beta-lactamase suicide inhibitor sulbactam. All subjects were hospitalized patients who received a daily dose of 9.0 to 12.0 gm of the compound administered parenterally every six to eight hours. All met requirements for assessment of efficacy and safety at the end of treatment and 17 of 19 were available for a follow-up assessment approximately two weeks after the last dose of the study drug. Sulbactam/ampicillin was found to be very efficacious with all patients reporting clinical cure or improvement, and a bacteriologic eradication rate of 89% at the end of therapy. Follow-up assessment approximately two weeks after the last dose of the study drug confirmed the clinical and bacteriologic efficacy of the compound. One patient presented a severe rash that disappeared after discontinuation of the drug, and no significant drug-related laboratory abnormalities were reported. Further studies are suggested to confirm what are very encouraging initial clinical findings.<p /><p>Language: en</p>",
language="en",
issn="0011-393X",
doi="",
url="http://dx.doi.org/"
}